News

Wall Street Trims Ratings for Novo Nordisk Stock, as Ozempic’s Competition Grows
Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...
Prediction: Eli Lilly's Newest GLP-1 Drug Will Be a Game-Changer for the Stock
Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...
Eli Lilly stock surges 15% after clinical trial of weight loss pill shows it works like Ozempic
The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of ...
Novo Nordisk: A Price Too Low To Ignore
Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.
Fake Ozempic drugs found in US drug supply, FDA warns
The FDA has issued a warning about counterfeit Ozempic medications, sharing the lot numbers and serial numbers of products ...
Fierce Pharma2d
Eli Lilly is overtaking Novo Nordisk in the diabetes, obesity market: BMO analysts
The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...
Futurism1d
Novo Nordisk Is Getting Absolutely Destroyed
Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight loss drugs Ozempic and Wegovy, have been absolutely plummeting. The company's stock price slid over ...
Novo Nordisk warns consumers about counterfeit versions of Ozempic in US
Danish drugmaker Novo Nordisk said on Monday several hundred counterfeit units of its diabetes drug Ozempic were being ...
Patients Cut Off From Cheaper Obesity Drugs as the F.D.A. Halts Sales of Copycats
U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...